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Editorial Comment 
Beta-Adrenergic Blockade and 
Acute Myocardial Infarction* 
C. RICHARD CONTI, MD, FACC 
Gainesville. Florida 
In this issue of the Journal, Jang et al. (1) present interesting 
data on the use of beta-adrenergic blockade in the experi- 
mental setting of coronary thrombosis and reperfusion. In 
their anesthetized dog model with single vessel occlusion, 
they were unable to show improvement in regional or global 
ventricular function with beta-blockade alone. In contrast, 
they showed an enhanced effect of thrombolysis on these 
variables by adding intravenous beta-adrenergic blockade 
with metoprolol early after the occlusion. Other experiments 
(2-4) in animals undergoing coronary reperfusion and then 
treated with beta-blockers suggest that beta-adrenergic 
blockade increases myocardial salvage. 
Limitations of the present study. The investigators iden- 
tified some limitations of their study as they might apply to 
humans. The first limitation relates to the amount of collat- 
eral flow during experimental occlusion. Collateral flow was 
not measured in the experimental animal, nor is it known in 
the human in the early stages of an acute myocardial 
infarction. One can hypothesize that in the animal or human 
with excellent collateral flow, intravenous metoprolol may 
be cardioprotective and limit the size of the infarct, whereas 
in the experimental animal or human without collateral flow, 
the same effect might not be observed. 
Beta-blockade will diminish myocardial oxygen con- 
sumption and perhaps, by that mechanism, limit infarct size. 
Changes in heart rate and blood pressure were not reported 
in the animal experiments. In humans, a fall in blood 
pressure and heart rate after intravenous beta-blockade 
might be much more dramatic than that observed in the 
anesthetized experimental animal. 
The second clinical limitation identijed by the investiga- 
tors is that intravenous metoprolol was administered very 
early after acute coronary artery occlusion, a procedure that 
might not be realistic when treating humans with acute 
myocardial infarction. I agree that these experimental results 
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may not apply strictly to the human situation, but we should 
consider two important points: 1) Many patients have been 
taking beta-blockers at the time of infarction (these patients 
obviously have beta-adrenergic blockade early on); 2) it is a 
clinical challenge to be certain when acute occlusion of the 
coronary artery occurs. A physician seeing the patient for 
the first time can consider only the history of chest pain, the 
physical findings and the electrocardiogram when deciding 
whether the patient is in the evolutionary stages of an 
infarction. Identical patients may have several hours of chest 
discomfort, yet one patient may have ischemia and the other 
patient infarction. In addition, what may appear to be a small 
uncomplicated infarction in the first few hours, may later 
become extensive and complicated. Thus, I believe that, 
unless beta-blocker therapy is contraindicated, its early use 
is worth considering in all patients with acute infarction, 
especially those receiving thrombolytic therapy. 
Clinical experience with early beta-blockade in myocardial 
infarction. It might be worth reviewing the results of clinical 
studies of intravenous blockade in the early stages of acute 
myocardial infarction. The routine use of beta-blockers in 
patients with an evolving myocardial infarction has been, 
and I believe remains, controversial. Administering a nega- 
tive chronotropic and a negative inotropic agent in the early 
phases of an acute myocardial infarction may be harmful, 
although this has not been shown in clinical trials. In the 
clinical trial conducted by The First International Collabo- 
rative Study Group (5), intravenous administration of timolol 
within 4 h of the onset of chest pain resulted in a reduction 
in myocardial ischemia and infarct size compared with 
findings after administration of placebo. In that study, 
timolol was administered intravenously for the first 24 h and 
then orally for the remainder of the day. 
The First International Study of Infarct Survival (ISIS-l) 
(6), a randomized trial at 245 centers in 14 countries, 
compared the beta-blocker atenolol (Tenormin) with placebo 
in 16,027 patients who were followed up for an average of 20 
months. Five milligrams of intravenous atenolol was given 
on admission, followed by another 5 mg, then 100 mg orally 
each day for the next 7 days. At 24 h there was a 30% 
reduction in mortality in patients who received atenolol, and 
a 15% reduction in mortality was maintained at 7 days. 
Twenty-eight random trials of intravenous beta-blockade 
for suspected or acute myocardial infarction have taken 
place (6). Overall, there was a reduction of mortality, 
reinfarction and cardiac arrest in patients receiving beta- 
blockers as compared with placebo. In addition, cardiac 
events over 0 to 7 days occurred in only 8.7% of 1,127 
patients receiving an intravenous beta-blocker compared 
with 10.3% of 1,312 patients receiving placebo. As part of 
the TIM1 trial (7), a study was done of a subgroup of patients 
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who were eligible to receive intravenous beta-blockers. 
Beta-blockade was generally well tolerated but did not alter 
mortality or left ventricular ejection fraction. However, the 
subsequent occurrence of nonfatal reinfarction and myocar- 
dial ischemia was reduced during the hospitalization. Those 
who benefited most received the drugs within 2 h of the onset 
of symptoms and were in the “low risk group.” Other 
clinical trials have shown a decreased mortality in patients 
receiving beta-blockers as compared with placebo. How- 
ever, beta-blockers were not administered in the early 
phases of acute myocardial infarction in most of these trials. 
A final clinical point! From the standpoint of safety, if 
there is early concern about the use of a beta-blocker in any 
acute syndrome, one should consider using an ultrashort- 
acting preparation, such as esmolol. The advantage of an 
ultra-short preparation is the rapid onset of action and 
disappearance of adverse effects in 15 to 20 minutes. 
Conclusions. It seems as though the weight of evidence 
favors the use of early beta-adrenergic blockade in patients 
with a recent myocardial infarction. However, I do not 
believe that prolonged beta-blocker therapy should be rec- 
ommended routinely in every patient who has survived a 
recent infarction. To illustrate this point, consider two 
patients. One has an inferior infarction, mild creatine kinase 
elevation due to an occlusion of a right coronary artery, a 
negative stress test before hospital discharge and otherwise 
normal coronary arteries. This patient must have an excep- 
tionally low risk of mortality over the next 12 months, and I 
doubt that he or she will benefit from prolonged beta- 
blockade. In contrast, a patient with a larger myocardial 
infarction, either inferior or anterior, a positive exercise test 
before discharge, premature ventricular beats on ambulatory 
ECG monitoring and multivessel coronary disease may be at 
much higher risk and may benefit from long-term beta- 
blockade. Thus, I continue to maintain that beta-blocker 
therapy must be individualized because these drugs are not 
benign and do have undesirable side effects. 
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